NCT02565979

Brief Summary

The main objective of the study is to investigate if 6 months resveratrol supplementation can improve glucose tolerance in overweight/obese individuals. As secondary objectives we want to investigate whether resting energy metabolism, intra-hepatic lipid content, physical performance, body composition and quality of life change by 6 months resveratrol supplementation in these individuals.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 1, 2015

Completed
6 months until next milestone

Study Start

First participant enrolled

April 1, 2016

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2019

Completed
27 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 28, 2019

Completed
Last Updated

April 2, 2019

Status Verified

March 1, 2019

Enrollment Period

2.9 years

First QC Date

September 30, 2015

Last Update Submit

April 1, 2019

Conditions

Keywords

ResveratrolDiabetes Mellitus, Type 2Insulin ResistanceMetabolic DiseasesGlucose Metabolism Disorders

Outcome Measures

Primary Outcomes (1)

  • Change in Glucose Tolerance

    Matsuda Index calculated from double 2-hour Oral Glucose Tolerance Test (OGTT)

    2x baseline and 2x after 6 months of supplemenation

Secondary Outcomes (8)

  • Change in Intra-hepatic lipid content

    baseline and after 6 months of supplemenation

  • Change in Resting energy expenditure

    baseline and after 6 months of supplemenation

  • Change in Body composition

    baseline and after 6 months of supplemenation

  • Change in Blood plasma markers

    Once a month for a period of 6 months

  • Change in Blood pressure

    Once a month for a period of 6 months

  • +3 more secondary outcomes

Study Arms (2)

Resveratrol

ACTIVE COMPARATOR

resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.

Dietary Supplement: resveratrol

Placebo

PLACEBO COMPARATOR

placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.

Dietary Supplement: placebo

Interventions

resveratrolDIETARY_SUPPLEMENT

Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.

Also known as: resVida (99% trans-resveratrol)
Resveratrol
placeboDIETARY_SUPPLEMENT

A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.

Placebo

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men aged 40-70 years and postmenopausal women aged 50-70 years
  • BMI: 27-35 kg/m2
  • Stable dietary habits: no weight gain or loss \> 5kg in the last three months
  • Willingness to limit consumption of resveratrol-containing food products and willingness to refrain from using resveratrol containing supplements
  • Subjects will only be included when the dependent medical doctor of this study approves participation after evaluating data obtained during screening

You may not qualify if:

  • Uncontrolled hypertension
  • HbA1c \> 6.5%
  • Previously diagnosed with type 2 diabetes
  • Medication use known to interfere with glucose homeostasis/metabolism
  • Current alcohol consumption \> 20 grams alcohol/day
  • Subjects who do not want to be informed about unexpected medical findings during the screening /study, or do not wish that their physician is informed, cannot participate in the study.
  • Participation in another biomedical study within 1 month before the start of the intervention
  • Any condition, disease or abnormal laboratory test result that, in the opinion of the Investigator, would interfere with the study outcome, affect trial participation or put the subject at undue risk

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maastricht University and Medical Centre

Maastricht, Limburg, 6200 MD, Netherlands

Location

Related Publications (1)

  • de Ligt M, Bergman M, Fuentes RM, Essers H, Moonen-Kornips E, Havekes B, Schrauwen-Hinderling VB, Schrauwen P. No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial. Am J Clin Nutr. 2020 Oct 1;112(4):1029-1038. doi: 10.1093/ajcn/nqaa125.

MeSH Terms

Conditions

Glucose IntoleranceDiabetes Mellitus, Type 2Insulin ResistanceMetabolic DiseasesGlucose Metabolism Disorders

Interventions

Resveratrol

Condition Hierarchy (Ancestors)

HyperglycemiaNutritional and Metabolic DiseasesDiabetes MellitusEndocrine System DiseasesHyperinsulinism

Intervention Hierarchy (Ancestors)

StilbestrolsStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolyphenolsPhenols

Study Officials

  • Patrick Schrauwen, Prof. Dr.

    Maastricht University Medical Centre

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 30, 2015

First Posted

October 1, 2015

Study Start

April 1, 2016

Primary Completion

March 1, 2019

Study Completion

March 28, 2019

Last Updated

April 2, 2019

Record last verified: 2019-03

Locations